Floatz logo

EXEMESTANE

FGFR Inhibition, Pharmacokinetics, Biomarkers

AstraZenecaSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the FGFR Inhibition, Pharmacokinetics, Biomarkers cohort.

Asset / SponsorPhaseRating
Fexagratinib
AstraZeneca
Phase 1/2CCC
FULVESTRANT
AstraZeneca
Phase 1/2CCC

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →